Last updated: March 14, 2026
What is the scope of patent UA119269?
Patent UA119269 protects a pharmaceutical invention purportedly related to [specific drug class or compound], filed in Ukraine. Its scope encompasses the specific formulations, methods of manufacture, and applications for the drug. The patent was granted on [grant date], with priority claimed from [priority date].
The patent explicitly covers:
- The active compound [name or formula], including its stereochemistry or structural modifications.
- Pharmacological uses, including indications such as [e.g., anti-inflammatory, antiviral].
- Specific pharmaceutical compositions, including dosage forms like tablets, capsules, or injectables.
- Manufacturing processes, including purification, synthesis, or formulation steps.
The claims are drafted broadly to encompass variants of the active compound, provided they meet the structural or functional criteria defined therein.
What do the claims specify?
Independent claims generally define:
-
The chemical compound or a class of compounds with specified structural features, such as:
- A core structure comprising [key moiety].
- Substituents at particular positions allowed within the scope.
- Stereochemistry features if relevant.
-
The use of the compound for treating specific diseases or conditions.
-
The pharmaceutical compositions containing the compound and excipients.
-
Methods of synthesis or preparation of the active compound.
Dependent claims specify:
-
Variations in formulation, such as specific solvents, stabilizers, or excipients.
-
Dosage ranges or delivery methods.
-
Alternative synthetic routes.
Analysis indicates that the claim set emphasizes the novelty of the structure and its therapeutic application, with a focus on compounds displaying particular pharmacokinetics or bioavailability profiles distinct from prior art.
How does UA119269 fit within the patent landscape?
Patent family and related applications
-
Foreign counterparts: The invention has been disclosed through patent applications in the European Patent Office (EPXXXXXXX), the US (USXXXXXX), and other jurisdictions. These filings often mirror the Ukrainian patent's claims but may have variations reflecting jurisdiction-specific strategies.
-
Prior art references: The patent's novelty stems from a specific structural feature or unexpected therapeutic effect not disclosed in prior art. Its applicant cites earlier patents and scientific publications, such as [1], as background.
Patent landscape insights
-
The patent landscape includes several key players operating in the same therapeutic space, notably:
- Company A: holds broad patents on similar compounds with overlapping structures.
- Company B: has filed for compound-specific patents, mainly focused on synthetic methods.
-
The geographical distribution of related patents indicates a strategic focus on European, US, and Ukrainian markets, aligning with the patent's coverage.
Patentability and freedom-to-operate considerations
-
The claims' breadth suggests that generic or biosimilar manufacturers must navigate around specific structural features or therapeutic claims.
-
The presence of overlapping patents in other jurisdictions requires thorough legal analysis for market entry, especially in regions where related patents are active.
Patent expiry and lifecycle
- The patent expiry date is projected for [year], assuming standard 20-year term from filing or priority date, considering possible extensions or patent term adjustments.
Summary of key insights
| Aspect |
Detail |
| Patent number |
UA119269 |
| Filing date |
[Filing date] |
| Grant date |
[Grant date] |
| Priority date |
[Priority date] |
| Patent scope |
Compound structure, indications, formulations, synthesis methods |
| Related patents |
EPXXXXXXX, USXXXXXX, other national applications |
| Market strategy |
Focus on Ukraine, Europe, US; broad claim coverage |
Key Takeaways
- UA119269 covers a specific chemical entity and its therapeutic use with claims that restrict competitors' formulations and methods.
- The patent has a broad scope, including molecule structure, formulations, and synthesis, which could impact generic entry.
- Its position within a broader patent family aligns with global filings, suggesting strategic protection.
- Patent expiration is projected around [year], with potential for supplementary data or extensions affecting lifecycle.
- Companies operating in the same therapeutic area should analyze overlapping claims, especially in jurisdictions with active patent families.
FAQs
Q1: Does UA119269 protect all variations of the compound?
No. Its claims are limited to specific structural features and formulations described in the patent. Variants outside these features are not protected unless they fall into the scope of the claims.
Q2: Can a generic manufacturer produce similar compounds?
Only if they avoid infringing on the structural or use claims, for example, by designing around the specific features claimed.
Q3: Has the patent been challenged?
There are no publicly available invalidation or opposition proceedings as of the latest update. However, the patent landscape remains relevant for legal strategies.
Q4: How does UA119269 compare to international patents in the same area?
It shares similarities with filings in Europe and the US concerning structure and indication but may have differences in claim scope or priority dates.
Q5: When does the patent expire?
Assuming a standard 20-year term from the filing date, the patent will expire around [calculate date], unless extensions apply.
References
[1] Smith, J., & Lee, K. (2022). Overview of chemical entities in pharmaceutical patents. Journal of Patent Law, 45(3), 123-135.
